Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Genmab ( (GMAB) ).
On November 18, 2025, Genmab A/S announced a capital increase of 32,059 shares following the exercise of employee warrants, generating approximately DKK 43.2 million. This increase, which represents about 0.05% of the company’s share capital, will be listed on Nasdaq Copenhagen and is expected to be finalized shortly. The new shares are ordinary, freely transferable, and come with rights to dividends. This move reflects Genmab’s ongoing efforts to enhance its financial position and support its strategic goals in the biotechnology sector.
The most recent analyst rating on (GMAB) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.
Genmab’s strong financial performance and positive earnings call sentiment are the primary drivers of its score. The company’s strategic initiatives and solid valuation further support its potential, despite some technical indicators suggesting caution.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab is an international biotechnology company headquartered in Copenhagen, Denmark, focused on developing innovative and differentiated antibody therapeutics. Established in 1999, Genmab has a strong presence in North America, Europe, and Asia Pacific. The company is known for its next-generation antibody technology platforms and aims to transform the lives of people with cancer and other serious diseases by 2030.
Average Trading Volume: 2,110,388
Technical Sentiment Signal: Buy
Current Market Cap: $18.66B
For a thorough assessment of GMAB stock, go to TipRanks’ Stock Analysis page.